eISSN: 1644-4124
ISSN: 1426-3912
Central European Journal of Immunology
Current issue Archive Manuscripts accepted About the journal Special Issues Editorial board Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank
Search
1/2020
vol. 45
 
Share:
Send email
Share:
abstract:
Clinical immunology

Circulation autoantibodies against C-terminus of NuMA in patients with Behçet’s disease

Muhammad Hussain
1
,
Fuxin Ma
1
,
Peng Chen
1
,
Yaping Tian
2
,
Hongwu Du
1

  1. 112 Lab, School of Chemistry and Biological Engineering, University of Science and Technology Beijing, Beijing, China
  2. Department of Clinical Biochemistry, Chinese PLA General Hospital, Beijing, China
(Centr Eur J Immunol 2020; 45 (1): 86-92)
DOI: https://doi.org/10.5114/ceji.2020.94710
Online publish date: 2020/04/06
View full text Get citation
 
PlumX metrics:
Circulating autoantibodies have a close association with autoimmune diseases, which may be seen even in healthy individuals. These are also considered as promising source of new biomarkers in various autoimmune diseases. However, their profile is not completely understood till now. Here, we evaluated autoantibodies against nuclear mitotic apparatus protein located at the carboxy terminus (C-NuMA) in blood circulation of Han Chinese patients, using different technical approaches to discover pathological reaction leading to Behçet’s disease (BD). In the first step, the recombinant human carboxy-terminal region of NuMA peptide (C-NuMA) was over-expressed and purified. In the second step, the indirect immunofluorescence method was used with patients’ sera, and commercial anti-NuMA antibody was used to determine the NuMA as a potential autoantigen. Results were confirmed at cell level by western blots, indicating that two of ten patients with Behçet’s disease could react with the recombinant C-NuMA, and the presence of antibodies were further verified by immunoprecipitation technique. Finally, the corresponding immunoassay (ELISA) was developed and optimized with specific recombinant C-NuMA as an in vitro method to test the confirmed patients with Behçet’s disease. Our findings demonstrated that C-terminus of NuMA is an immune target of Behçet’s disease in Han Chinese patients.
keywords:

C-NuMA, antigen epitope site, autoantibody, nuclear protein
Termedia
About us Contact
Copyright notice Privacy policy Advertising policy Contact us
Quick links
Journals Books eBooks Events
© 2024 Termedia Sp. z o.o.
Developed by Bentus.